Back to top
more

P10 (PX)

(Real Time Quote from BATS)

$7.49 USD

7.49
32,763

-0.06 (-0.80%)

Updated Apr 30, 2024 10:38 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

5-Strong Sell of 5         5

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value D Growth A Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 44% (141 out of 251)

Industry: Financial - Miscellaneous Services

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

What Lies Ahead for Materials ETFs?

by Zacks Equity Research

China threatens to retaliate if the United States moves ahead with tariffs on metal imports.

    Monsanto Battles Market Rivalry on Innovation & Bayer's Deal

    by Zacks Equity Research

    Monsanto Company's (MON) performance to be driven by stronger innovation and Bayer AG's pending buyout deal. However, stiff business rivalry and rising debt remain causes of concern.

      Mark Vickery headshot

      Top Analyst Reports for Johnson & Johnson, Illinois Tool Works & BNY Mellon

      by Mark Vickery

      Today's Research Daily features new research reports on 14 major stocks, including Johnson & Johnson (JNJ), Illinois Tool Works (ITW) and Bank of New York Mellon (BK).

        Praxair (PX) Tops Q4 Earnings, Linde Merger to Close in 2H18

        by Zacks Equity Research

        Praxair's (PX) fourth-quarter 2017 adjusted earnings benefit from solid segmental performance, partially offset by rise in costs and expenses.

          Praxair Inc. (PX) Beats Q4 Earnings and Revenues

          by Zacks Equity Research

          Praxair Inc's (PX) fourth-quarter 2017 earnings surpassed the Zacks Consensus Estimate by 2.7% while revenues surpassed by 3.6%.

            Praxair (PX) Secures Gas Supply Contract From EverDisplay

            by Zacks Equity Research

            Praxair, Inc. (PX) fortifies business in China on the back of recently-secured long-term gas supply deal from EverDisplayOptronics.

              Should You Buy Praxair (PX) Ahead of Earnings?

              by Zacks Equity Research

              Praxair (PX) is seeing encouraging earnings estimate revision activity as of late and carries a favorable rank, positioning the company for a likely beat this season.

                Will Demand & Contract Wins Aid Praxair's (PX) Q4 Earnings?

                by Zacks Equity Research

                Praxair's (PX) Q4 earnings are likely to gain from strengthening end-market demand and growing applications for industrial gases.

                  Praxair (PX) Extends Hydrogen Supply Contract With Motiva

                  by Zacks Equity Research

                  Increasing application of industrial gases in manufacturing, transportation, healthcare, food and beverages, and metal fabrication industries is beneficial for Praxair (PX).

                    Mark Vickery headshot

                    Top Stock Reports for PepsiCo, Walgreens Boots & EOG Resources

                    by Mark Vickery

                    Today's Research Daily features new research reports on 16 major stocks, including PepsiCo (PEP), Walgreens Boots (WBA) and EOG Resources (EOG).

                      Can Sucampo Acquisition Turn Mallinckrodt Stock Around?

                      by Zacks Equity Research

                      Mallinckrodt (MNK) faced challenging business conditions in 2017 and the company is now looking to revive business with the recently announced Sucampo acquisition.

                        Mallinckrodt to Buy Sucampo for $1.2B to Diversify Portfolio

                        by Zacks Equity Research

                        Mallinckrodt (MNK) is all set to acquire Sucampo Pharmaceuticals to diversify its portfolio and counter the decline in sales of its largest drug, Acthar.

                          Here's Why You Should Hold on to Praxair (PX) Stock Now

                          by Zacks Equity Research

                          Praxair (PX) is well-poised to gain traction from solid contract wins, capital allocation policy and diversified business structure. Industry competition and rising costs remain issues.

                            Praxair Hikes Gas Prices to Cover High Energy & Labor Costs

                            by Zacks Equity Research

                            Praxair (PX) is poised to gain from increasing applications of industrial gases. Up to 15% hike in gas prices will help it recover increasing costs.

                              Why Is Praxair (PX) Up 4.5% Since the Last Earnings Report?

                              by Zacks Equity Research

                              Praxair (PX) reported earnings more than 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

                                Mallinckrodt (MNK) Down 55% Year to Date: What Lies Ahead?

                                by Zacks Equity Research

                                Mallinckrodt plc (MNK)'s stock lost 55% in the year so far due to ongoing investigations and weakness in Acthar and Inomax.

                                  Materials ETFs Head to Head: XLB vs. IYM

                                  by Zacks Equity Research

                                  Head to Head comparison of two financials ETFs, XLB and IYM.

                                    Praxair (PX) Tops Q3 Earnings on Sales Growth, Ups '17 View

                                    by Zacks Equity Research

                                    Praxair's (PX) third-quarter 2017 adjusted earnings benefitted from higher sales in all segments but were adversely impacted by high costs and expenses.

                                      Praxair Inc. (PX) Beats Q3 Earnings and Revenues

                                      by Zacks Equity Research

                                      Praxair Inc's (PX) third-quarter 2017 earnings surpassed the Zacks Consensus Estimate by 4.2% while revenues surpassed by 1.8%.

                                        Key Predictions for Earnings Reports of APD, EMN & PX

                                        by Zacks Equity Research

                                        Chemical companies are expected to continue the earnings momentum in the September quarter as the fundamental driving factors remained firmly in place.

                                          Will Regional Uncertainties Hurt Praxair's (PX) Q3 Earnings?

                                          by Zacks Equity Research

                                          Praxair's (PX) Q3 earnings are likely to gain from improving market conditions, benefits from contract wins and product launches in the prior quarter. Forex issues and stiff competition are concerns.

                                            Praxair-Linde Merger Approved by Russian Body, Wins Contract

                                            by Zacks Equity Research

                                            Russian antitrust consent for Praxair's (PX) and Linde merger marks a step forward for creation of a leading industrial gas company. Also, Praxair's China-gas supply deal will strengthen its business.

                                              Praxair Gains From Contract Wins, Solid Demand, Risks Remain

                                              by Zacks Equity Research

                                              Praxair (PX) will gain from diversified business structure, solid product demand and contract wins. High debt, stiff competition and global uncertainties remain issues.

                                                Top Research Reports for Boeing, Schlumberger & JPMorgan

                                                by Zacks Equity Research

                                                Today's Research Daily features new research reports on 12 major stocks, including Boeing (BA), Schlumberger (SLB) and JPMorgan (JPM).

                                                  Mallinckrodt Down as District Court Invalidates Inomax Patents

                                                  by Zacks Equity Research

                                                  Shares of Mallinckrodt plc (MNK) were down 12.3% after a U.S. District Court invalidated 11 patents covering its second-largest product Inomax.